Self-Administered Etripamil Safe, Effective for Paroxysmal Supraventricular Tachycardia
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, Sept. 29, 2023 -- Investigational etripamil nasal spray is well tolerated for self-treating recurrent episodes of paroxysmal supraventricular tachycardia (PSVT) without medical supervision, according to a study published online Sept. 27 in the Journal of the American Heart Association.
James E. Ip, M.D., from Weill Cornell Medicine and the NewYork-Presbyterian Hospital in New York City, and colleagues conducted an open-label extension of the phase 3 NODE-301 to assess the safety and efficacy of the L‐type calcium channel blocker etripamil. The analysis included 105 patients who were monitored via a self-applied cardiac monitoring system for five hours after etripamil self-administration for PSVT.
The researchers found that during a median 232 days of follow-up, the probability of conversion within 30 minutes of etripamil was 60.2 percent (median time to conversion, 15.5 minutes) among 188 PSVT episodes (92 patients) positively adjudicated as atrioventricular nodal-dependent by independent electrocardiogram analysis. Forty patients self-treated two PSVT episodes, and among these participants, three-quarters had a significantly consistent response by 30 minutes, nine did not convert on either episode, and 21 converted on both episodes. Treatment-emergent adverse events occurred in 42.9 percent of patients, which were generally transient and mild-to-moderate (e.g., nasal congestion [14.3 percent], nasal discomfort [14.3 percent], or rhinorrhea [12.4 percent]). Within 24 hours of etripamil self-administration, no serious cardiac safety events were seen.
"This is a potential new and exciting option for patients to safely self-treat their rapid heartbeat without direct medical supervision to avoid emergency room visits and medical interventions," Ip said in a statement.
Several authors disclosed ties to pharmaceutical companies, including Milestone Pharmaceuticals, which manufactures etripamil and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Survival Possible for Some With TBI for Whom Treatment Was Withdrawn
MONDAY, May 13, 2024 -- A substantial proportion of patients with traumatic brain injury (TBI) who undergo withdrawal of life-sustaining treatment (WLST) could have survived and...
Study Identifies Factors Associated With Hydroxychloroquine Retinopathy
MONDAY, May 13, 2024 -- Factors associated with an increased risk for hydroxychloroquine retinopathy have been identified and include female sex, older age, and chronic kidney...
Adding Cardiovascular Biomarkers to Established Risk Factors Increases Risk Prediction
MONDAY, May 13, 2024 -- The addition of cardiovascular biomarkers to established risk factors leads to a small improvement in risk prediction of cardiovascular disease, according...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.